==== Front Bone Res Bone Res Bone Research 2095-4700 2095-6231 Nature Publishing Group UK London 119 10.1038/s41413-020-00119-9 Review Article Neurological heterotopic ossification: novel mechanisms, prognostic biomarkers and prophylactic therapies http://orcid.org/0000-0001-7874-0672Wong Ker Rui 1 Mychasiuk Richelle 1 O’Brien Terence J. 12 Shultz Sandy R. 12 McDonald Stuart J. 13 Brady Rhys D. rhys.brady@monash.edu 12 1 grid.1002.30000 0004 1936 7857Department of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC Australia 2 grid.1008.90000 0001 2179 088XDepartment of Medicine, Royal Melbourne Hospital, The University of Melbourne, Parkville, VIC Australia 3 grid.1018.80000 0001 2342 0938Department of Physiology, Anatomy and Microbiology, School of Life Sciences, La Trobe University, Bundoora, VIC Australia 9 12 2020 9 12 2020 2020 8 4215 4 2020 20 8 2020 16 9 2020 © The Author(s) 2020Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.Neurological heterotopic ossification (NHO) is a debilitating condition where bone forms in soft tissue, such as muscle surrounding the hip and knee, following an injury to the brain or spinal cord. This abnormal formation of bone can result in nerve impingement, pain, contractures and impaired movement. Patients are often diagnosed with NHO after the bone tissue has completely mineralised, leaving invasive surgical resection the only remaining treatment option. Surgical resection of NHO creates potential for added complications, particularly in patients with concomitant injury to the central nervous system (CNS). Although recent work has begun to shed light on the physiological mechanisms involved in NHO, there remains a significant knowledge gap related to the prognostic biomarkers and prophylactic treatments which are necessary to prevent NHO and optimise patient outcomes. This article reviews the current understanding pertaining to NHO epidemiology, pathobiology, biomarkers and treatment options. In particular, we focus on how concomitant CNS injury may drive ectopic bone formation and discuss considerations for treating polytrauma patients with NHO. We conclude that understanding of the pathogenesis of NHO is rapidly advancing, and as such, there is the strong potential for future research to unearth methods capable of identifying patients likely to develop NHO, and targeted treatments to prevent its manifestation. Subject terms DiseasesBonehttps://doi.org/10.13039/100000065U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS)NINDS RFA-NS-16-012Shultz Sandy R. issue-copyright-statement© The Author(s) 2020 ==== Body Introduction Heterotopic ossification (HO) is the pathological formation of bone in muscles and surrounding joints. The ramifications of this ectopic bone formation in soft tissue include swelling, pain, nerve entrapment, contractures, and in some cases, limited range of movement due to bone fusion in the affected area (i.e. ankylosis).1 Although various forms of hereditary and acquired HO exist, HO that occurs following a neurological insult (i.e. neurological HO; NHO) is of increasing clinical concern due to its rising prevalence in combat and civilian populations.2 Neurological heterotopic ossification (NHO) is particularly common when a neurological insult, such as a traumatic brain injury (TBI) or spinal cord injury (SCI), occurs in the presence of concomitant peripheral injuries (e.g. bone fractures, muscle injuries). Non-surgical interventions include analgesia,3 rest,4 and nerve blockers;5 however, the only cure is surgical excision.6,7 Unfortunately, invasive surgical excision can only occur once the lesion has mineralised, and reoccurs in ~6% of patients.8 Consequently, there is an urgent need to develop prophylactic interventions that can prevent HO and are still appropriate for patients who have sustained severe trauma to the periphery and central nervous system (CNS).9 To date, the development of prophylaxes has been hindered by a limited understanding of how ectopic bone formation is triggered in response to CNS and musculoskeletal trauma. Nonetheless, there has been a recent rise in the number of clinical and pre-clinical studies designed to unearth the cellular and molecular mechanisms of NHO. This article will first review the literature regarding NHO epidemiology, the pathophysiology of CNS injuries, and how they may promote bone formation, mechanisms of endochondral bone formation before presenting new research avenues towards identifying novel mechanisms of NHO, and the limited NHO treatment options. As the literature specific to NHO is relatively limited, we sometimes draw from the broader HO literature and make inferences where relevant. Epidemiology and risk factors for NHO It has been reported that at least 10%–20% of patients with a TBI and simultaneous peripheral musculoskeletal injuries (i.e. polytrauma involving substantial muscle injuries and bone fractures) develop NHO.10–13 Following combined SCI and polytrauma, ~15%–30% of patients develop NHO.10–12 This ectopic bone has a tendency to form predominantly in muscle surrounding the hip, although it also frequently affects other joints such as the knee, elbow, and shoulder (see Table 1).10–12 Notably, when NHO is formed posteriorly at the hip, it often entraps the sciatic nerve, resulting in neurological pain and muscle weakness, impaired movement, and difficulty performing everyday tasks (e.g. standing, sitting and getting dressed).10,14 Most studies suggest that NHO prevalence is significantly higher in males than females, which has been attributed to the increased number of males that experience a TBI or SCI.15 However, a recent study employing a mouse model of HO (featuring a dermal burn and Achilles tenotomy) reported that male mice formed ~30% more ectopic bone when compared to female mice, possibly due to increased insulin like growth factor-1 and bone morphogenetic protein (BMP) signalling in males.16 Therefore, males may be predisposed to having increased risk for the development of HO/NHO.Table 1 Incidence, demographics and locations of NHO reported across the literature Author Description (total number of patients, age range, mean age, gender, number of patients with NHO) Type of injury/s Location of HO and imaging modality used Reznik et al.165 262 TBI patients, 226 M, 36 F TBI-NHO patients: 10, mean: 39.6 years, 10 M 151 SCI patients, 128 M, 23 F 16 SCI-NHO patients, mean: 31.4 years, 13 M, 3 F TBI and SCI Hip: 17 lesions, shoulder: 1 lesion, elbow: 3 lesions, knee: 5 lesions Bone scintigraphy Dizdar et al.20 151 TBI patients, 126 M, 25 F 56 NHO patients, mean: 34.6 years, 48 M, 8 F TBI Hip: 41 patients, shoulder: 11 patients, elbow: 20 patients, knee: 25 patients, ankle: 2 patients Imaging modality: not reported (NR) Van Kampen et al.22 176 TBI patients, 75 M, 22 F 13 TBI-NHO patients, mean: 34.65 years, 10 M, 3 F 79 excluded GCS <8. Coma duration in NHO group: 15 days Coma duration in non-NHO group: 4.18 days Mechanical ventilation: 17.23 days Immobilisation days: 13.46 TBI Concomitant bone FX: 8/13 patients Hip: 3 lesions, shoulder: 2 lesions, thigh: 2 lesions, elbow: 4 lesions, knee: 5 lesions, femur: 1 lesion, ankle: 1 lesion, iliopsoas muscle: 1 lesion Imaging modality: NR Rigaux et al.166 31 TBI patients, 31 M 12 TBI-NHO patients, 33 years,12 M GCS: ≥8 3 months-post-injury TBI NR X-ray, bone scintigraphy Hurvitz et al.167 90 TBI patients, mean: 11.9 years, 67 M, 23 F 13 TBI-NHO patients, 9 M, 4 F 35 patients TBI + extremity FX 30 patients TBI + skull FX TBI Hip: 4 lesions, shoulder: 3, femur: 3, elbow: 3, knee: 4 lesions, forearm: 2, ischium: 2 X-ray, bone scintigraphy Hendricks et al.168 76 TBI patients, 16–84 years, mean: 36.67 years, 47 M 29 F 9 TBI-NHO patients GCS 3: 9 Coma duration of 76 patients: 10.03 (1–61 days) Mechanical ventilation: 8.95 (0–52 days) Diffuse axonal injury: 7 patients TBI Concomitant bone FX: 9/9 patients Hip: 5 lesions, shoulder: 3 lesions, elbow: 5, knee: 5, ankle: 2 Seipel et al.169 1 463 total patients, 17–77 years, mean: 40.4 years, 916 M, 547 F 30 NHO patients, 23 M, 7 F Mean time to HO diagnosis: 7.2 ± 1.2 weeks TBI and SCI TBI/SCI: 23 patients Concomitant peripheral trauma: 5 patients Non traumatic: 7 patients Hip: 42 lesions, shoulder: 22 lesions, elbow: 7 lesions, knee: 10 lesions, upper ankle joint: 1 lesion, diaphysis of long bones: 3 lesions X-ray Singh et al.170 18 SCI patients, 18–54 years, mean: 32 years, 16 M, 2 F 7 SCI-NHO patients, 18–40 years, mean: 30 years Average abbreviated injury scale (AIS): A Average HO score: 1a SCI Hip: 7 patients X-ray, SPECT Wittenberg et al.171 413 SCI patients, mean: 35.4 years, 274 M, 82 F 71 SCI-NHO patients, mean: 33.8 years, 63 M, 8 F 30 tetraplegia, 39 paraplegia 57 excluded from study SCI Concomitant head injuries: 23 patients Concomitant extremity injury: 19 patients Concomitant pelvic injury: 1 patient Concomitant injuries (abdominal and thoracic): 33 patients Left hip: 70.4%, right hip 57.8% Elbow: 5, knees, 2 X-ray Bravo-Payno et al.172 654 SCI patients 85 SCI-NHO patients, 18–56 years, 29.70 years 41 excluded from study SCI Hip: 36 patients, shoulder: 3 patients, elbow: 1 patient, knee: 4 patients X-ray Orzel and Rudd173 50 total patients 43 NHO patients, 18–56 years, 30 M, 13 F SCI, TBI, peripheral trauma (cerebral vascular insult, burn) SCI trauma: 27 Paraplegics: 17 Closed head injury: 7 Peripheral trauma: 8 Hip: 33 patients, shoulder: 8 patients, thigh: 10 patients, elbow: 8 patients, knee: 3 patients, leg: 1 patient Bone scintigraphy F female, M male, NR not reported, TBI traumatic brain injury, SCI spinal cord injury, NHO neurological heterotopic ossification, FX fracture, SPECT single-photon emission computed tomography aHO grade according to Brooker classification Whether individuals are genetically predisposed towards NHO formation has not yet been established. Initial investigations have examined the association between human leukocyte antigen (HLA) serotypes and NHO; although, there has been contradicting evidence regarding the role of HLA-B27.17,18 In a clinical study involving 43 patients with a SCI, five of the 21 patients that developed NHO were positive for HLA-B27 compared to none of the 22 patients without NHO.17 However, the hypothesis that HLA-B27 may be a genetic risk factor for NHO was challenged by a separate study that found no differences in the frequency of any HLA-A and HLA-B antigens in 24 NHO patients compared to 740 healthy controls.18 Further large-scale studies are required to determine the link between HLA antigens, and other genetically determined factors, that may contribute to NHO. Several risk factors have been linked to NHO formation, including coma duration, artificial or mechanical ventilation, duration of immobilisation, elevated serum alkaline phosphatase (ALP) levels, and the presence of TBI featuring diffuse axonal injury.8,19–21 Patients with TBI-induced NHO often have longer mechanical ventilation and coma duration when compared to TBI patients who do not develop NHO; nevertheless, the exact relationship between coma duration and NHO formation is yet to be established.22 It has been proposed that the homoeostatic balance between calcium, oxygen, and pH levels are altered via artificial ventilation, which may result in respiratory alkalosis, contributing to accelerated ectopic bone formation.19 However, as increased coma duration is often the result of more severe injuries, it is difficult to determine the effect it has on NHO. These factors may contribute to the increased prevalence of NHO in patients following a stroke, TBI, or SCI. Recent studies have identified an increased propensity to develop NHO following combat-related trauma, such as blast-TBI (bTBI) and limb amputations.23 A recent study on Iraq war operations reported that ~80% of injuries were the result of explosive devices (e.g. improvised explosive devices, mortar, or mines).24 Tissue damage caused by bTBI is induced by a combination of shockwaves, supersonic flow and highly heated air flow, resulting in a string of consequences that involve thermal injury, cavitation, and increased intracranial pressure.25 An initial study examined the prevalence of NHO/HO during the recent conflict in Iraq and Afghanistan.26 Approximately 70% of patients exposed to blast injuries requiring at least one orthopaedic procedure developed HO, while 86% of patients who experienced a bTBI and orthopaedic procedures developed NHO.26 Furthermore, univariate analysis demonstrated a significant relationship between HO and TBI severity. These findings demonstrate that the aetiology of polytrauma is incredibly heterogeneous, and as such, NHO may require several therapeutic approaches.27 Pathophysiology of CNS injury TBI and SCI both induce an array of pathophysiological alterations that may stimulate either formation or resorption of bone.28,29 Briefly, acceleration–deceleration and/or rotational forces at the moment of impact can induce significant damage to neurons, glia and the vasculature, triggering a complex cascade of cellular and molecular changes that may contribute to further damage over the ensuing hours, days and months following injury. Common secondary injury mechanisms involved in TBI/SCI can include excitotoxicity, ionic imbalances, mitochondrial dysfunction, oxidative stress, neuroinflammation, ischaemia and edema.30,31 Notably, damage to the blood–brain barrier (BBB) or blood spinal cord barrier (BSB), the semi-permeable anatomical interfaces that separate the brain and spinal cord from peripheral blood circulation,32 creates potential for abnormal passage of molecules and cells in and out of the brain and spinal cord.33–36 For example, substances that are highly concentrated in the CNS (e.g. neuropeptides) or increased following injury (e.g. inflammatory mediators, growth factors) can migrate into the peripheral circulation, and thereby potentially drive NHO formation. This notion is supported by findings that serum and CSF from TBI patients has been found to increase osteoblastic proliferation.37,38 Furthermore, prolonged pituitary dysfunction is common after TBI,39,40 with alterations to the release of hormones such as parathyroid hormone41 and growth hormone,42 which may influence musculoskeletal tissues and potentially contribute to NHO development. CNS injury may promote bone formation For quite some time, orthopaedic surgeons have observed that peripheral bone fracture callus formation appears to be significantly enhanced in patients with a TBI. More recently, several clinical studies have supported this anecdotal evidence of increased callus size in TBI patients.43–45 However, human studies of this nature are often are confounded by variations in the location, nature and severity of both the bone fracture and TBI. Rodent studies that control for these variables have since demonstrated that TBI increases volume and strength of newly formed bone within the healing callus at acute and sub-acute time-points.46–51 This phenomenon may also occur following SCI, with a recent study finding that SCI patients with femoral fracture had increased callus volume and accelerated rate of fracture union when compared to patients with an isolated femoral fracture.52 A preliminary study in mice has implicated the involvement of neuronal mechanisms in robust callus formation following TBI.53 It was reported that mice that received a fracture contralateral to the site of TBI had increased callus bone volume at 5 days post injury when compared to fracture-only mice, whereas callus bone volume in mice that were given a TBI ipsilateral to the fracture was comparable to fracture-only mice.53 In contrast to the aforementioned studies,46–51 these differences, however, were not observed at later time-points (i.e. 10 or 14 days post injury).53 These findings led the authors to suggest that neuronal mechanisms play a significant role in increasing bone formation acutely following TBI by causing contralateral activation of fracture healing.53 It still remains unclear as to how TBI/SCI can alter callus formation; however, it appears likely TBI/SCI-induced NHO share a common mechanism. It is important to acknowledge that in the absence of a peripheral bone fracture, both TBI and SCI have been associated with reduced bone mineral density in rodents,54,55 and humans.29 These findings may indicate that cellular and molecular changes due to tissue damage (e.g. inflammation) at a peripheral site is required to stimulate NHO and fracture callus formation. Overall, the mechanisms responsible for the paradoxical effects that CNS injuries have on bone are yet to be elucidated. Mechanisms of endochondral HO The process of ectopic bone formation in trauma induced HO is thought to occur via endochondral (rather than intramembranous) ossification. Although the precise mechanisms are not well characterised, a pool of osteoprogenitor cells (OPCs) residing in skeletal muscle combined with factors that are increased in response to trauma, such as inflammatory cells and molecules, enhanced BMP signalling, and hypoxia are thought to create an environment that together facilitates formation of bone by endochondral ossification.56,57 The formation of ectopic endochondral bone begins with invasion of immune cells, including neutrophils, macrophages, mast cells.2,57 The influx of inflammatory factors to the often hypoxic and acidic peripheral injury site is thought to stimulate the differentiation of OPCs to fibroblasts, which is driven by expression of fibroblast growth factors (FGFs), which form fibrous tissue.58–60 In response to hypoxia, expression of hypoxia-inducible factor-1 alpha (HIF-α) and vascular endothelial growth factor are upregulated to stimulate angiogenesis which provides a conduit for cells to migrate to the injury site.61 Moreover, a hypoxic environment induces expression of transcription factor SOX-9, which promotes the differentiation of chondrocytes by activating SOX-9 in a HIF-1α dependent manner.62 These chondrocytes then undergo hypertrophy and begin to form a cartilaginous matrix.63–65 Subsequent remodelling of this cartilage is mediated by matrix metalloproteinases and results in the release of angiogenic factors that further promote vascular invasion.66 The cartilage is then removed as the lesion begins to mineralise. Over time the initial woven bone is then remodelled to form mature lamellar bone with a marrow cavity. Of interest, sources of OPCs have not yet been established, however it has been suggested that that induction of OPCs from muscle satellite cells cause HO formation.19,67,68 Other studies suggest that the source of OPCs are from fibroadipogenic progenitors that reside within the muscle interstitium, but are not exclusive to muscle.69 It is possible that identification of the exact source of these OPCs may facilitate the design of better therapeutic strategies to prevent HO formation. There is little information regarding whether the mechanisms of NHO differ from HO, but it is important to establish as it has ramifications for identifying potential druggable targets for each condition. For example, although peripheral trauma associated HO is thought to occur exclusively via endochondral ossification, it is not yet known whether the additional presence of neurotrauma may alter the frequency of endochondral vs. intramembranous ossification. Additionally, an initial human study provides evidence that the histological mechanisms of ectopic bone formation were identical in lesions from TBI, SCI and trauma induced HO.70 However, significant heterogeneity existed between the location of HO, furthermore the time-point that the HO was excised was not stated. Therefore, it is difficult to determine whether the mechanisms differ between HO and NHO in the acute phase, (i.e. before mineralisation). For a more in-depth description of the cellular and molecular mechanisms of HO formation, the reader is referred to the following reviews.71–75 Mechanisms of HO formation following CNS injury Current understanding of the cellular and molecular mechanisms of HO formation specifically in the context of neurotrauma is lacking; however, there are a number of potential mechanisms through which CNS injury may promote formation of ectopic bone at peripheral injury sites (summarised in Fig. 1). Indeed, the past decade has seen the emergence of animal models of polytrauma that have shed some light on the key drivers of HO formation following TBI or SCI. Herein, we outline emerging evidence and hypotheses of the mechanisms of NHO formation, with a particular focus on the potential role of macrophages and neuropeptides.Fig. 1 Proposed mechanism for NHO development. Simultaneous injury to the CNS and peripheral sites triggers the release of osteogenic and inflammatory factors including; SP, CGRP, OSM, IL-6, BMPs and FGFs. The influx of osteogenic and inflammatory factors, initiates the differentiation of OPCs into fibroblasts which is mediated by fibroblast growth factors (FGFs). This influx also elicits angiogenesis, which results in an increase in oxygen tension, triggering the differentiation of OPCs into chondrocytes which undergo hypertrophy and form a cartilage matrix. This cartilaginous matrix provides a structural framework for the formation of blood vessels, osteoblast proliferation and differentiation and formation of ectopic bone (created with BioRender.com) Role of inflammatory cells and mediators Macrophages and neutrophils Macrophages and neutrophils have been identified as prominent cells of the muscle inflammatory infiltrate in the acute and sub-acute phases post injury and may contribute to NHO. Work by Genet et al. has highlighted the contribution of F4/80+ resident tissue macrophages as key drivers of SCI-induced NHO.12 Following SCI and cardiotoxin induced muscle injury, mice were injected intravenously with clodronate-loaded liposomes to deplete resident tissue macrophages.12 Ablation of these resident tissue macrophages was found to reduce NHO volume by ~90%, and completely prevent NHO development in 3/11 mice.12 These findings indicate that macrophages likely play a prominent role in SCI-induced NHO formation. Resident tissue macrophages have previously been implicated in the development of HO, however it still remains unclear as to whether the contribution of resident tissue macrophages differs between HO and NHO. To the best of our knowledge, to date no studies have compared the effect of resident tissue macrophage depletion in HO and NHO models. However, in a model of HO induced by burn and tenotomy, although injection of mice with clodronate-loaded liposomes decreased total HO volume by ~50%, HO was still observed in all mice.76 Although further studies are required, taken together these findings suggest that the contribution of resident tissue macrophages may differ between HO and NHO. A number of factors released by macrophages are also released by neutrophils, therefore to determine the role of neutrophils in SCI-induced NHO, Tseng et al. recently examined NHO formation in neutropenic mice.77 Neutrophil depletion had no effect on NHO volumes.77 Nor did treatment with rhG-CSF which significantly increased the number of neutrophils in the blood, bone marrow and injured muscles.77 These findings suggest that macrophage related factors in combination with CNS injury drive NHO. OncostatinM Oncostatin M (OSM) is an inflammatory cytokine, derived from activated macrophages, osteoclasts, monocytes, T cells, and neutrophils.78,79 OSM has been reported to stimulate osteoblastic differentiation and hence bone formation by acting on osteoclasts and osteoprogenitors.80 The involvement of OSM in osteogenic differentiation in NHO development suggests that OSM receptor (OSMR) and OSM could be viable therapeutic targets.78 A recent study examined NHO formation using NHO-lesions from 64 patients with CNS injuries (SCI, TBI, stroke, or cerebral anoxia) and a mouse model of SCI-induced NHO.78 Histological analysis of NHO-lesions excised from CNS-injured patients revealed that OSM was expressed by CD68+ macrophages and osteoclasts within NHO sections.78 Of note, OSM plasma protein levels were elevated twofold when compared to healthy donors (i.e. HO negative patients following total hip surgery), suggesting that plasma OSM levels may serve as a biomarker of NHO formation.78 It was also found that muscle-derived stromal cells isolated from NHO-lesions expressed OSMRs, and that treatment with recombinant human OSM increased mineralisation and differentiation.78 In addition, after SCI-induced NHO in mice, immunohistochemistry and mRNA analysis demonstrated that OSM levels were significantly increased in injured muscle post-CDTX injection and SCI, and that OSM is secreted and accumulates at the site of NHO.78 Furthermore, deletion of the OSMR receptor significantly reduced NHO volume (median volume 14.2 mm3 in wild type, 3.2 mm3 in OSMR knockouts). Considered together, these findings suggest that OSM produced by resident tissue macrophages drives NHO formation by stimulating differentiation and mineralisation of muscle stromal cells and that OSM may represent a plasma marker and therapeutic target for preventing/reducing NHO formation.78 The contribution of OSM to TBI-induced NHO is yet to be elucidated in a suitable model, as an animal model of TBI-induced NHO that accurately mimics the combinations of injuries that these patients often present with has only recently been developed.81 Briefly, this model features a concomitant femoral muscle crush injury, femoral fracture and a moderate-severe brain injury in rats, where 70% of rats that underwent these injuries developed ectopic bone at the peripheral injury site.81 Role of neuropeptides Neuronal injury can trigger neurogenic inflammation, which in the context of moderate-severe TBI or SCI has been shown to exacerbate secondary injury pathologies such as neuronal cell death,82 BBB83 and BSB,82 oedema,83 ischaemia83 and hypoxia.84 Neurogenic inflammation has been associated with the release of neuropeptides, particularly substance P (SP) and calcitonin gene related protein (CGRP) which increases vascular permeability and vasodilation respectively.85 Impairment of the BBB following trauma can promote further propagation of neurogenic inflammatory factors, causing exacerbated neural injury.86 Notably, there is now emerging evidence that release of these neuropeptides into peripheral circulation after neurotrauma may be a key driver of NHO formation. SubstanceP SP is a neuropeptide that is distributed throughout the central and peripheral nervous system, with increasing evidence highlighting its role in neurogenic inflammation, bone remodelling and TBI pathology.87,88 SP has previously been identified as a potential therapeutic target that contributes to NHO and HO development.12,89,90 SP possesses a strong affinity to neurokinin-1 receptor (NK-1R) belonging to the tachykinin receptor group.91 Accumulating evidence indicates that SP contributes to NHO development. For instance, several human and animal studies have reported that SP levels are elevated in the blood following TBI and SCI.92,93 Most notably, the role of SP in NHO has been studied in patients a murine model of SCI-induced NHO.12 SP concentrations were significantly higher in plasma from NHO patients compared to healthy volunteers. While in the mouse model, antagonising SP receptor NK-1R with RP67580 reduced NHO volume by ~30%.12 These findings indicate that SP may represent both a prognostic biomarker of NHO and a treatment target, whereby an intervention that downregulates SP is initiated following elevated plasma levels of SP. Mast cell degranulation has been reported to be essential for SP to induce HO formation.94,95 Further, mast cells also release serotonin, which is known to have dual functions in bone remodelling dependent upon the site of production and it has been proposed that serotonin may drive adipocyte differentiation, creating a further hypoxic microenvironment for NHO formation.96 With respect to TBI-induced NHO, the role of SP has yet to be examined. However, the release of SP following TBI is associated with increased BBB permeability, brain oedema formation, as well as increased intracranial pressure, which contributes to neuronal cell death after the initial trauma.97 Therefore, it is likely that targeting SP may affect NHO either acting locally by preventing ectopic bone formation at the peripheral injury site or by acting centrally where attenuating TBI outcomes may result in reduced NHO volume. Altogether, these findings propose that SP does play a significant role in both NHO and HO formation. Given the essential role of SP in acute CNS injuries, further studies need to be carried out to potentially use SP as a therapeutic target and blood-based biomarker of NHO.98 Calcitonin gene related protein (CGRP) CGRP is a sensory neuropeptide that is distributed in both the CNS99 and PNS.100 In the CNS, CGRP is expressed in cerebral cortex, hippocampus and hypothalamus,99 while in the CNS99 and PNS100 can be found in sensory, motor neurons and often colocalizes with SP.100 The upregulation of CGRP following TBI is also thought to contribute to neurogenic inflammation.85 While the precise role of CGRP in the development of NHO remains to be elucidated, in a mouse model of SCI-induced NHO significantly elevated levels of CGRP were found within the injured muscle 14 days post injury.101 In vitro, CGRP was found to promote the differentiation of fibroadipogenic progenitor cells to chondrocytes.101 Interestingly, studies in rodents have revealed that TBI,102–104 or SCI104 concomitant with fracture elevates CGRP serum levels, with these animals having accelerated bone healing. This suggests that increased expression of CGRP following CNS trauma and peripheral injury may contribute to heterotopic bone formation by triggering neurogenic inflammation; however, further studies examining the relationship between SP, CGRP and NHO are required to determine its exact mechanism. Other neuropeptides Neurotrophins such as nerve growth factor (NGF), neurotrophin-3 (NT-3), neutrophin-4 (NT-4), and brain-derived neurotrophic factor have all been associated with alterations in bone metabolism. NGF is responsible for the growth and maintenance of neuronal and non-neuronal cells in both PNS and CNS.105 However, a growing body of evidence suggests that NGF and NT-3 may play a role in skeletal development,106 fracture healing107–109 and HO.110 For example, in a rat model of HO which features bilateral midpoint Achilles tenotomy, mRNA expression of NT-3 was significantly (100-fold), while NGF levels were more modestly increased (<20-fold) from 4 weeks to 12-week post-tenotomy.110 The role that these neuropeptides play in NHO is yet to be reported in the literature. Disrupted neural signalling There is increasing recognition that bone modelling and remodelling can be regulated by the CNS, with hypothalamic leptin signalling being a key regulator of bone remodelling.111 Although the precise mechanisms are unclear, it has been theorised that central regulation of bone formation occurs via activation of efferent pathways relayed via the brainstem.111,112 As such, damage or alterations in excitability of these neural pathways following TBI or SCI may also be a contributor to NHO formation. Supporting this hypothesis, ventromedial hypothalamic neurons have been identified as playing a key role in bone formation, with chemical lesioning of these neurons resulting in a high bone mass phenotype in mice.113 This was thought to occur via ablation of leptin receptors which are densely populated in this region, thus inhibiting the osteogenic effect of leptin.113 Indeed, future studies are required to elucidate the role of efferent signalling on NHO, as well as the effect that lesions to different structures of the brain have on TBI-induced NHO. Treatments for NHO In this section, an overview of existing therapeutic interventions for NHO will be provided. These approaches are summarised in Fig. 2. These strategies include surgical resection of completely mineralised ectopic bone, radiotherapy, non-steroidal anti-inflammatory drugs (NSAIDs) and bisphosphonates. In addition, important considerations for these treatments in the context of polytrauma involving CNS injury are discussed.Fig. 2 Current treatments targeting specific pathways of NHO. NHO development is triggered by a cascade of inflammatory factors. Presently, the preferred prophylactic treatment for NHO/HO involves NSAIDs (e.g. Indomethacin) to downregulate the inflammatory response and prevent OPC differentiation. Radiotherapy is thought to prevent the formation and development of ectopic bone specifically by inhibiting the differentiation of OPCs. RAR-γ agonists have been shown to prevent chondrogenesis and therefore subsequent mineralisation. While, nitrogen-containing bisphosphonates (e.g. sodium etidronate) have been used to inhibit mineralisation, and the formation of ectopic bone. Finally, when bone is completely mineralised, surgical resection is the only remaining intervention. This invasive procedure, however, is accompanied by the risk of recurrence and is associated with complications which include incomplete resection, functional and physiological impairment (created with BioRender.com) Surgical excision Presently, invasive surgical resection is the only effective clinical approach to cure NHO.6,7 However, it is recommended that surgery should only be considered if NHO patients fulfil the following criteria: (1) a significant reduction in range of motion (ROM) due to joint ankylosis, (2) an absence of acute inflammatory response and (3) the lesion is sufficiently mineralised (mature) to enable excision.1,114,115 However, several other factors are also to be considered when deciding the timing of surgical intervention. Previous studies have found that to reduce the risk of recurrence, surgical excision is preferred after ectopic bone has fully mineralised.10,116,117 Following SCI and TBI, resection was traditionally performed >12–18 months-post injury.1,118 Over the past decade there has been a shift in the clinical management of NHO to favour earlier resection i.e. surgery is performed as soon as the patient is stable enough to undergo surgery and the lesion is sufficiently mineralised to enable resection.8,119–121 These changes were based on findings that earlier resection of NHO-lesions did not in fact increase the risk of recurrence.8,119–121 Further, recent evidence suggests that early excision may reduce the risk of operative complications (e.g. peri-operative fracture), enhance bone and articular cartilage health, and reduce negative cerebral changes (e.g. atrophy of motor areas) that further inhibit ROM (see Table 2).11,118,122Table 2 Treatments for clinical and radiographical evidence of HO/NHO reported across literature Author Description (total number of patients, age range, mean age, gender, number of patients with NHO) Injury and imaging modality used to confirm NHO Location of NHO and treatment/s Reported recurrence and complications Surgical resection Meiners et al.174 29 SCI-NHO patients, 27–68.13 years, mean: 37.87 years, 28 M, 1 F 41 lesions Cervical lesions of spinal cord: 10 patients Thoracic spine lesions: 19 patients SCI X-ray Hip Dose: average: 9.17 Gy, range: 0.7–12 Gy in 1–5 sessions Mean follow-up: 4.2 years Mean time to surgery: 82.1 months (17–298 months) Indications for surgery: seating problems, loss of functions, pressure sore, pain Preoperative ROM: 21.95° (range: 0–80°) Postoperative ROM: 82.68° (range: 0–120°) Recurrence: 3 patients Complications: deep and superficial wound infections, fracture, aneurysm and pressure ulcer Hunt et al.175 42 burns patients, 22–62 years, mean: 38 years 42 burn-HO patients, 22–62 years, mean: 38 years 47 lesions Mean TBSA: 55% Mean third degree burn: 37% Average ventilator support: 58 days Burn injuries X-ray Hip, elbow, forearm Indications for surgery: decreased ROM resulting in loss of functions in daily activities, ulnar nerve entrapment, inability to perform physical therapy Preoperative ROM: 52° Postoperative ROM: 119° Recurrence in 6 elbows, 1 hip and 1 forearm Complications: ulnar nerve deficit, numbness weakness, small haematoma, minor wound dehiscence and cellulitis. Radiation therapy Hamid et al.134 45 patients with elbow trauma, 18–65 years, mean: 44 years, 25 M, 20 F 20 elbow trauma-HO patients Intraarticular distal humeral fracture, Fracture-dislocation with proximal radial and/or ulnar fracture X-ray, CT scan Elbow Dose: 700 cGy single fraction dose at 6-MeV photons), N = 21 Mean follow-up: 7.5 months (range: 6–26 months) Mean time to treatment: 72 h Indications for treatment: seating problems, loss of functions, decubitus, pressure sore, pain Preoperative ROM: 21.95° (range: 0–80°) Postoperative ROM: 82.68° (range: 0–120°) Trial was terminated early due to high non-union rate observed in the radiation treatment group Recurrence: 0 Complications: infection (2), non-union (8) Stein et al.176 11 patients with elbow trauma, 28–78 years, mean: 51 years, 3 M, 8 F 3 elbow trauma-HO patients, 54–78, mean: 63 years, 1 M, 2 F 3 lesions Fracture/dislocation of the elbow Radiographs 11 patients Dose: 700 cGy single non-fractionated at unreported MeV Mean follow-up: 12 months (range: 9–24 months) Mean time to treatment: 5 days (range: 0–16 days) Indications for treatment: NR Preoperative ROM: NR Postoperative ROM: 114.5° (range: 0–135°) Recurrence: 0 Complications: decreased sensation along ulnar nerve Müseler et al.177 244 SCI-NHO patients, 18–81 years, mean: 46.4 years, 207 M, 37 F, 444 lesions AIS A—12 patients (4 tetraplegic 8 paraplegic) AIS B—1 patient (1 tetraplegic) SCI CT scan or MRI Radiation therapy (7 Gy, single dose accompanied by 15MV or 6MV) Mean follow-up: 89.4 days Mean time to treatment: 3.7 days Indications for treatment: NR Recurrence: 13 patients (26 joints) Complications: NR Cipriano et al.178 60 NHO-patients, mean: 36.7 years, 47 M, 13 F 72 lesions TBI, SCI, TBI + SCI, TBI + local trauma 30 patients Dose: 700 cGy dose of radiation Mean follow-up: 12.7 months (range: 6–33 months) Mean time to treatment: 1.18 days (range: 0–4 days) Indications for treatment: limited ROM, nerve impingement, reduced quality of life and functions Preoperative ROM: Postoperative ROM: Hip—4.23°, Hip—67.2° Knees—81.3°, Knees—117.5° Elbows—4.0°, Elbows—140.0° Recurrence: 6 joints Complications: NR NSAIDs Banovac et al.138 33 SCI-NHO patients AIS A—13 (5 tetraplegics, 7 paraplegic) AIS B—1 (1 tetraplegic) AIS C—2 (2 paraplegic) AIS D—1 (1 tetraplegic) SCI Bone scintigraphy (early stage) X-ray (later stage) 16 patients Oral indomethacin 75 mg daily, IV disodium etidronate, 300 mg daily for 3 days, oral etidronate, 20 mg·kg−1 per day for 6 months Mean follow-up: 1.5 months Mean time to treatment: 21 days Indications for treatment: local erythema, swelling, loss of joint ROM and fever Recurrence in 2 patients Complications: upper abdominal discomfort Banovac et al.179 76 SCI patients, 65 M, 11 F AIS A—28 patients AIS B—8 patients AIS C—1 patient SCI Bone scintigraphy, radiograph 37 patients Oral rofecoxib 25 mg daily, IV disodium etidronate 300 mg daily for 3 days, oral etidronate, 20 mg·kg−1 per day for 6 months Mean time to treatment: 25 days Indications for treatment: local oedema, fever and decreased joint ROM Recurrence in 5/37 patients Complications: NR Romano et al.180 400 THA patients, mean: 61.2 years 24 excluded (due to side effects) Coxarthrosis, femoral head necrosis Radiograph 250 patients Rectal indomethacin 50 mg daily for 2 days, a day post-surgery followed by oral indomethacin 50 mg daily for 18 days 150 patients Celecoxib 200 mg daily for 2 days, starting 2 days post-surgery for 20 days Mean follow-up: 12 months Mean time to treatment: 1 and 2 days respectively Indomethacin: 40 patients, Celecoxib: 21 patients Complications: (Indomethacin) gastrointestinal side effects, excessive bleeding, mental confusion (Celecoxib), nausea and gastrointestinal pyrosis Schmidt et al.181 201 THA patients, 28–89, mean: 67.5 years Total hip replacement Radiograph 102 patients Oral indomethacin 25 mg, thrice daily, for 6 weeks, starting on first postoperative day Mean follow-up: 12 days Mean time to treatment: 1 day Recurrence in 13 patients Complications: NR Bedi et al.182 616 patients after hip arthroscopy, mean: 31.3 years, 342 M, 274 F 29 HO patients, 15–57 years, mean: 30.6 years, 21 M, 8 F Hip arthroscopy Radiographs, CT scan 277 patients Naproxen (500 mg, twice daily for 30 days, starting a day post-surgery) 339 patients Indomethacin 75 mg daily for 4 days, Naproxen 500 mg, twice daily for 30 days Mean follow-up: 13.2 months (range: 2.9–16.5 months) Mean time to treatment: 1 day 7 patients HO surgical excision, radiation therapy 700 cGy, single dose Mean time to treatment: 11.6 months (range: 5.2–16.2 months) Naproxen only: 23 patients have HO Naproxen + Indomethacin: 6 patients Complications: NR Beckmann et al.183 106 patients after hip arthroscopy, mean: 35 years, 40 M, 66 F Excluded from study: n = 10 Hip arthroscopy Radiographs 52 patients Naproxen 500 mg, twice daily for 3 weeks, post-surgery Mean time to treatment: 1 day Indications for treatment: pain, radiographic abnormalities and evidence of labral tear on MRI Recurrence: 2 Complications: Gastrointestinal discomfort, rash, blood clot, heartburn, headache and pain Neal et al.184 2 649 THA patients, mean: 65.5 years, 1 311 M, 1 338 F 601 excluded 627 lesions Hip arthroplasty Radiograph 1 039 patients Aspirin 162 mg·d−1 for 35 days post-surgery Mean follow-up: 22 months Recurrence: 627 patients Complications: hip pain (with the need for analgesia), difficulty or restriction of mobility Bisphosphonates Schuetz et al.185 7 patients in total, 47–68 years, mean: 54.8 years, 7 M 5 patients with HO, 47–68 years, mean: 54.8 years, 5 M Number of lesions: 8 Caisson disease, tetraplegia, e.coli sepsis, osteoarthritis, FOP Radiographs IV pamidronate 680 mg/850 mg/1200 mg Mean follow-up: 19.6 months (range: 4–54 months) Indications for treatment: pain, hardening at operation site and decreased ROM Recurrence in 1 patient Complications: need for pain medication, lower back pain Orzel and Rudd173 50 patients 43 NHO patients, 18–56 years, 30 M, 13 F 81 lesions SCI paraplegia, closed head injury, peripheral trauma, cerebral vascular insult, burn Bone scintigraphy 14 patients Oral etidronate disodium 20 mg·kg−1 for first 2 weeks followed by 10 mg·kg−1 for remainder of study Mean follow-up: 22.5 months Indications for treatment: Radiograph evidence No response to therapy in 4/14 Complications: NR Banovac154 40 SCI-NHO patients, mean: 23 years, 39 M, 1 F AIS A—37 patients (16 are tetraplegic, 21 are paraplegic) AIS B—3 patients (2 are tetraplegic, 1 is paraplegic) SCI Radiograph and bone scintigraphy 40 patients IV etidronate sodium 300 mg, 3 doses for 3 days followed by oral etidronate sodium 20 mg·kg−1 per day for 6 months Mean follow-up: 35 months Indications for treatment: oedema, reduced ROM, fever, positive scintigraphy Recurrence in 2 patients, Complications: NR Banovac et al.152 27 SCI patients, 16–54 years, mean: 36 years, 25 M, 2 F 11 SCI-NHO patients 3 excluded SCI Bone scintigraphy 24 patients IV etidronate disodium (300 mg for 3 h, 3 doses for 3 days/5 days) followed by oral etidronate sodium (20 mg·kg−1 per day for 6 months) Indications for treatment: acute swelling, reduced ROM, increased body temperature, laboratory test (increased serum alkaline phosphatase, accelerated erythrocyte sedimentation rate) and positive bone scintigraphy Recurrence: 11 patients Garland et al.151 75 SCI-patients 14 SCI-NHO patients, 17–30 years, mean: 25 years 5 excluded 14 lesions SCI Radiograph, bone scintigraphy 9 patients Sodium etidronate 20 mg·kg−1 per day for 2 weeks followed by 10 mg·kg−1 per day for 2 years Mean follow-up: 14 months (range: 5–19 months) Mean time to treatment: 26.7 days (range: 0–55 days) Indications for treatment: swelling, reduced ROM Recurrence: none Complications: none F female, M male, NR not reported, TBI traumatic brain injury, SCI spinal cord injury, NHO neurological heterotopic ossification, ROM range of motion, TBSA total body surface area (%), THA total hip arthroplasty, FOP fibrodysplasia ossificans progressive Resection has however been associated with a number of complications. For example, complete excision of periarticular NHO is particularly difficult, with patients often left with persistent decreases in ROM. Lesion remnants can result in both functional and physiological impairment due to impingement of neurovascular bundles, ankylosis, and pain.10,118,123–125 Like any other invasive procedures, post- and intra-operative NHO excision is associated with potential blood loss and infection—both complications that may have a substantial effect on TBI or SCI recovery. Moreover, surgical removal can damage adjacent peripheral tissues, and recurrence at the site of excision is common.123,126–129 As such, surgical intervention is not an optimal NHO therapy and should be carefully considered. Radiation therapy Radiation therapy is thought to prevent the formation and/or progression of HO by inhibiting the differentiation of OPCs.114 Specifically, in vitro studies have demonstrated that radiotherapy inhibits BMP-2 signalling, reduces osteoblastic proliferation and differentiation, and promotes apoptosis.130,131 In an initial pre-clinical study, adult rats implanted with de-mineralised bone matrix were administered radiation at 2-, 4-, 6-, 8-, 10- and 12 days post-implantation.132 Implanted rats went on to form ectopic bone at 11 days post-implantation.132 It was noted that rats that underwent radiation at 2- or 4 days post-implantation had reduced HO volume by ~60% and 24% respectively. However, when radiation was delayed until 8 days post-implantation, the authors observed no difference in HO volume between rats that were irradiated and controls.132 Several studies have reported beneficial effects of administering radiotherapy to prevent NHO post-TBI and SCI, or to prevent the recurrence of NHO (i.e. post-excision; see Table 2).133–135 For example, in a phase I/II clinical study, 33 SCI patients that underwent radiotherapy observed no further ectopic bone growth, however joint mobility was mildly affected in three patients.133 In some cases, the risk of impaired fracture healing can be prevented in radiotherapy by adequately shielding the surrounding areas of interest; however, this can be difficult when ectopic bone forms close to fractures and around amputation sites. In one particular clinical study where patients with elbow injuries underwent radiation therapy, eight of the 21 patients experienced fracture non-union, whereas for the 24 patients that did not undergo radiotherapy, only one experienced non-union.134 In addition to fracture healing, radiation therapy can also disrupt wound healing, and has been associated with an increased risk of malignancy.136 Therefore, the use of radiotherapy in polytrauma NHO patients is often contraindicated.137 Non-steroidal anti-inflammatory drugs (NSAIDs) NSAIDs have been successfully used to prevent ectopic bone formation following SCI and hip arthroplasty (see Table 2). While NSAIDs such as celecoxib and meloxicam have been used to prevent NHO, indomethacin, a non-selective COX-1 and COX-2 inhibitor, is currently considered the gold standard for preventing NHO formation and progression.118,138 The effect of indomethacin has been demonstrated in a rat model of HO that features subcutaneous implantation of de-mineralised bone matrix.139 When indomethacin was administered 6 h prior to the implantation, there was a reduction in area of ectopic bone, ALP activity, and calcium content when compared to controls.139 However, when indomethacin was administered at the time of de-mineralised matrix implantation or post-implantation (6 h, 1 d, 2 d, 3 d, and 4 d), there were no differences in ectopic bone area, ALP activity, and calcium content when compared to controls.139 Despite the proven efficacy of NSAIDs for treating NHO, it is important to recognise that there are reports of potentially negative adverse effects of these agents on patients with polytrauma. For example, rofecoxib, a highly selective COX-2 inhibitor was frequently prescribed to prevent HO.140 However, it was withdrawn from the market following a randomised, placebo-controlled, double-blind clinical trial that found chronic use elevated the risk of serious cardiovascular events (i.e. heart attack and stroke) in patients taking it to prevent the recurrence of colorectal polyps.140 Furthermore, evidence suggests that indomethacin may interfere with fracture healing.141,142 A study in rats reported that indomethacin treatment diminished mechanical properties of femoral fracture calluses.141 This finding suggests that indomethacin treatment is problematic, particularly in patients with concomitant fracture. In addition, ibuprofen, a commonly prescribed NSAID, may worsen cognitive outcome after severe TBI in rats.143 Further, rats given a TBI and administered celecoxib, a COX-2 inhibitor often administered to HO patients, had worse motor performance.144 In some circumstances COX-1 inhibitors have been associated with an increased prevalence of gastrointestinal side effects such as bleeding and perforations.145,146 NSAIDs also have a limited therapeutic window and are only effective in the early stages of HO development, prior to the formation of ectopic bone (Fig. 2). Once bone deposition has occurred, NSAIDs are ineffective, hence surgical intervention remains the only option. Overall, despite the efficacy of NSAIDs in preventing/reducing ectopic bone formation, these findings support the notion that careful consideration must be taken before administering NSAIDs to polytrauma patients. Bisphosphonates Bisphosphonates are commonly used to treat bone disorders such as osteopenia, osteoporosis, and Paget’s disease by reducing osteoclastic bone resorption.147 Nitrogen-containing bisphosphonates, such as risedronate, sodium etidronate, and alendronate, are often prescribed as prophylaxis due to their ability to effectively prevent mineralisation.148 In vitro, treatment of osteoblasts with nitrogen-containing bisphosphonates, pamidronate and alendronate, at doses of 10−4–10−5 mol·L−1 (therapeutic doses range in humans is between 10−5 and 10−9 mol·L−1) results in osteoblastic apoptosis directly, and/or indirectly via osteoblast cell cycle arrest and cell proliferation inhibition.149,150 These findings were not observed when cells were treated with non-nitrogen-containing bisphosphonates.150 The use of nitrogen-containing etidronate in ectopic bone formation has been well documented.151–154 However, some studies do not recommend sodium etidronate as treatment for NHO.151,153 As bisphosphonates suppress bone resorption and accumulate in the body for an extended period of time, adverse effects associated with high doses include amassed bone microdamage which is frequently observed with old age, hence further contributing to increased skeletal fragility.155,156 In addition, due to the potentially negative impacts on skeletal fragility combined with the high cost of bisphosphonates, it would be beneficial to identify those patients who are at risk of developing NHO, and treat only them with bisphosphonates.157 It is also unknown how bisphosphonates affect TBI and SCI outcomes, which should be considered in NHO patients. Retinoic acid receptor agonist Retinoic acid receptors (RAR) are mediators of skeletal development via the Smad complex, that plays an integral role in chondrogenesis.158 An RAR-γ agonist, palovarotene, has shown to be effective in preventing the initial stages of NHO.159 The authors developed a model that mimics the injury combinations and bioburden that occurs in blast related combat injuries.159 Palovarotene significantly decreased NHO by inhibiting the expansion as well as differentiation of OPCs into chondrocytes.159 Further, palovarotene treatment was found to downregulate mRNA expression of chondrocytic (SOX-9 and collagen2α1) and osteoblastic (OC, OPN, BMP-2, BMP-4, POU5FL and RUNX2) genes Fig. 3.159–161 RAR-γ activation, however has been shown to delay growth plate development. Therefore, several studies have warned that precautions should be taken when administering an RAR-γ agonist to children.160,162 Whereas in adults, it was proposed that RAR-γ treatment could be given intermittently, henceforth providing sufficient recovery time for the growth plate.160,162 Furthermore, as palovarotene has also been shown to inhibit fracture healing care should be taken when administering to patients with healing fractures.162–164 Nonetheless, activation of RAR-γ still shows promising results as a novel therapeutic agent in preventing progression of NHO.Fig. 3 Key pathways/mechanisms implicated in the development of NHO highlighting potential and existing therapeutic targets to mitigate NHO. a Substance P receptor (NK-1R) antagonists (e.g. RP67580) have been found to reduce NHO volume in murine models. b Downstream of the BMP pathway, RAR-γ agonists such as palovarotene have been reported to prevent early stages of NHO development by disrupting OPC differentiation, chondrogenesis and osteogenesis by downregulating mRNA expression of SOX-9 and RUNX2. c OSM is a potential therapeutic target and may serve as a biomarker for NHO. Blocking OSM has been found to reduce NHO likely by inhibiting downstream transcription factor, STAT3, which is known to trigger bone formation. d NSAID, indomethacin is currently the preferred prophylaxis for NHO/HO. It targets COX-1 and COX-2 non-selectively, inhibiting the production of prostaglandins and osteogenesis (created with BioRender.com) Conclusion The development of NHO is relatively common after TBI and SCI, and typically occurs in the presence of concomitant significant peripheral musculoskeletal injuries. The majority of NHO cases are diagnosed following extensive mineralisation, at which stage patients are likely to experience considerable pain and disruption to daily functional activities. Current treatments are limited in effectiveness and not always suitable for NHO patients, and there are no reliable prognostic biomarkers to identify patients at high risk of developing NHO to guide preventative interventions. Fortunately, there are numerous promising avenues for future research to identify new underlying pathophysiological mechanisms related to NHO, prognostic biomarkers, and prophylactic therapies that are suitable for complex trauma patients with CNS injuries. These future studies would benefit from a complementary translational approach that incorporates improved clinically relevant animal models in parallel with more rigorous clinical investigations. In doing so, there is the strong potential to develop biomarkers and prophylactic strategies to improve NHO patient outcomes. Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Acknowledgements R.B. is supported by a grant from NINDS (NINDS RFA-NS-16-012) to T.O.B. and S.S. S.S. is supported by a fellowship from NHMRC. Competing interests The authors declare no competing interests. ==== Refs References 1. Garland, D. E. A clinical perspective on common forms of acquired heterotopic ossification. Clin. Orthop. Relat. Res.263, 13–29 (1991). 2. Hoyt BW Pavey GJ Potter BK Forsberg JA Heterotopic ossification and lessons learned from fifteen years at war: a review of therapy, novel research, and future directions for military and civilian orthopaedic trauma Bone 2018 109 3 11 10.1016/j.bone.2018.02.009 29462673 3. Citta-Pietrolungo TJ Alexander MA Steg NL Early detection of heterotopic ossification in young patients with traumatic brain injury Arch. Phys. Med. Rehabil. 1992 73 258 262 1543430 4. Mavrogenis AF Soucacos PN Papagelopoulos PJ Heterotopic ossification revisited Orthopedics 2011 34 177 10.3928/01477447-20110124-08 21410128 5. Adiguzel E Knee pain relief with genicular nerve blockage in two brain injured patients with heterotopic ossification Brain Inj. 2015 29 1736 1739 10.3109/02699052.2015.1075171 26479687 6. Brady RD Shultz SR McDonald SJ O’Brien TJ Neurological heterotopic ossification: current understanding and future directions Bone 2018 109 35 42 10.1016/j.bone.2017.05.015 28526267 7. Davis EL Davis AR Gugala Z Olmsted-Davis EA Is heterotopic ossification getting nervous?: the role of the peripheral nervous system in heterotopic ossification Bone 2018 109 22 27 10.1016/j.bone.2017.07.016 28716552 8. Genêt F Troublesome heterotopic ossification after central nervous system damage: a survey of 570 surgeries PLoS ONE 2011 6 e16632 10.1371/journal.pone.0016632 21304993 9. Maheswarappa B Nair K Taly A Shanthi S Murali T Heterotopic ossification at unusual site in traumatic brain injury IJPMR 2004 15 34 37 10. Cipriano CA Pill SG Keenan MA Heterotopic ossification following traumatic brain injury and spinal cord injury J. Am. Acad. Orthop. Surg. 2009 17 689 697 10.5435/00124635-200911000-00003 19880679 11. Nauth A Heterotopic ossification in orthopaedic trauma J. Orthop. Trauma 2012 26 684 688 10.1097/BOT.0b013e3182724624 23010648 12. Genêt F Neurological heterotopic ossification following spinal cord injury is triggered by macrophage‐mediated inflammation in muscle J. Pathol. 2015 236 229 240 10.1002/path.4519 25712044 13. Jodoin M Investigating the incidence and magnitude of heterotopic ossification with and without joints involvement in patients with a limb fracture and mild traumatic brain injury Bone Rep. 2019 11 100222 10.1016/j.bonr.2019.100222 31463337 14. Salga M Sciatic nerve compression by neurogenic heterotopic ossification: use of CT to determine surgical indications Skelet. Radiol. 2015 44 233 240 10.1007/s00256-014-2003-6 15. Frost RB Farrer TJ Primosch M Hedges DW Prevalence of traumatic brain injury in the general adult population: a meta-analysis Neuroepidemiology 2013 40 154 159 10.1159/000343275 23257914 16. Ranganathan K Role of gender in burn-induced heterotopic ossification and mesenchymal cell osteogenic differentiation Plast. Reconstr. Surg. 2015 135 1631 1641 10.1097/PRS.0000000000001266 26017598 17. Larson JM Increased prevalence of HLA-B27 in patients with ectopic ossification following traumatic spinal cord injury Rheumatology 1981 20 193 197 10.1093/rheumatology/20.4.193 18. Hunter T Dubo H Hildahl C Smith N Schroeder M Histocompatibility antigens in patients with spinal cord injury or cerebral damage complicated by heterotopic ossification Rheumatology 1980 19 97 99 10.1093/rheumatology/19.2.97 19. Sakellariou V Grigoriou E Mavrogenis A Soucacos P Papagelopoulos P Heterotopic ossification following traumatic brain injury and spinal cord injury: insight into the etiology and pathophysiology J. Musculoskelet. Neuronal Interact. 2012 12 230 240 23196266 20. Dizdar D Risk factors for developing heterotopic ossification in patients with traumatic brain injury Brain Inj. 2013 27 807 811 10.3109/02699052.2013.775490 23730889 21. Simonsen LL Sonne-Holm S Krasheninnikoff M Engberg AW Symptomatic heterotopic ossification after very severe traumatic brain injury in 114 patients: incidence and risk factors Injury 2007 38 1146 1150 10.1016/j.injury.2007.03.019 17572418 22. Van Kampen P Martina J Vos P Hoedemaekers C Hendricks H Potential risk factors for developing heterotopic ossification in patients with severe traumatic brain injury J. Head Trauma Rehabil. 2011 26 384 391 10.1097/HTR.0b013e3181f78a59 21321512 23. Forsberg, J. A. & Potter, B. K. Heterotopic Ossification in Wartime Wounds. J. Surg. Orthop. Adv. Spring.19, 54–61 (2010). 24. Taber KH Warden DL Hurley RA Blast-related traumatic brain injury: what is known? J. Neuropsychiatry Clin. Neurosci. 2006 18 141 145 10.1176/jnp.2006.18.2.141 16720789 25. Rosenfeld JV Blast-related traumatic brain injury Lancet Neurol. 2013 12 882 893 10.1016/S1474-4422(13)70161-3 23884075 26. Forsberg JA Heterotopic ossification in high-energy wartime extremity injuries: prevalence and risk factors J. Bone Jt. Surg. Am. 2009 91 1084 1091 10.2106/JBJS.H.00792 27. Clark ME Scholten JD Walker RL Gironda RJ Assessment and treatment of pain associated with combat-related polytrauma Pain Med. 2009 10 456 469 10.1111/j.1526-4637.2009.00589.x 19416437 28. Alizadeh A Dyck SM Karimi-Abdolrezaee S Traumatic spinal cord injury: an overview of pathophysiology, models and acute injury mechanisms Front. Neurol. 2019 10 282 10.3389/fneur.2019.00282 30967837 29. Smith E Comiskey C Carroll A Prevalence of and risk factors for osteoporosis in adults with acquired brain injury Ir. J. Med. Sci. 2016 185 473 481 10.1007/s11845-016-1399-5 26787314 30. Maas AI Stocchetti N Bullock R Moderate and severe traumatic brain injury in adults Lancet Neurol. 2008 7 728 741 10.1016/S1474-4422(08)70164-9 18635021 31. Blennow K Hardy J Zetterberg H The neuropathology and neurobiology of traumatic brain injury Neuron 2012 76 886 899 10.1016/j.neuron.2012.11.021 23217738 32. Alves JL Blood-brain barrier and traumatic brain injury J. Neurosci. Res. 2014 92 141 147 10.1002/jnr.23300 24327344 33. Stamatovic SM Keep RF Andjelkovic AV Brain endothelial cell-cell junctions: how to “open” the blood brain barrier Curr. Neuropharmacol. 2008 6 179 192 10.2174/157015908785777210 19506719 34. Wilson EH Weninger W Hunter CA Trafficking of immune cells in the central nervous system J. Clin. Investig. 2010 120 1368 1379 10.1172/JCI41911 20440079 35. Wolburg, H., Wolburg-Buchholz, K. & Engelhardt, B. Involvement of tight junctions during transendothelial migration of mononuclear cells in experimental autoimmune encephalomyelitis. Ernst Schering Res. Found. Workshop.47,17–38 (2004). 36. Shlosberg D Benifla M Kaufer D Friedman A Blood-brain barrier breakdown as a therapeutic target in traumatic brain injury Nat. Rev. Neurol. 2010 6 393 403 10.1038/nrneurol.2010.74 20551947 37. Bidner SM Rubins IM Desjardins JV Zukor DJ Goltzman D Evidence for a humoral mechanism for enhanced osteogenesis after head injury J. Bone Jt. Surg. Am. 1990 72 1144 1149 10.2106/00004623-199072080-00004 38. Gautschi OP Osteoinductive effect of cerebrospinal fluid from brain-injured patients J. Neurotrauma 2007 24 154 162 10.1089/neu.2006.0166 17263679 39. Quinn M Agha A Post-traumatic hypopituitarism—who should be screened, when, and how? Front. Endocrinol. 2018 9 8 10.3389/fendo.2018.00008 40. Tan CL The screening and management of pituitary dysfunction following traumatic brain injury in adults: British Neurotrauma Group guidance J. Neurol. Neurosurg. Psychiatry 2017 88 971 981 10.1136/jnnp-2016-315500 28860331 41. Silva BC Bilezikian JP Parathyroid hormone: anabolic and catabolic actions on the skeleton Curr. Opin. Pharmacol. 2015 22 41 50 10.1016/j.coph.2015.03.005 25854704 42. Lindsey RC Mohan S Skeletal effects of growth hormone and insulin-like growth factor-I therapy Mol. Cell. Endocrinol. 2016 432 44 55 10.1016/j.mce.2015.09.017 26408965 43. Cadosch D Humoral factors enhance fracture-healing and callus formation in patients with traumatic brain injury J. Bone Jt. Surg. Am. 2009 91 282 288 10.2106/JBJS.G.01613 44. Giannoudis PV Accelerated bone healing and excessive callus formation in patients with femoral fracture and head injury Injury 2006 37 S18 S24 10.1016/j.injury.2006.08.020 16963358 45. Perkins R Skirving A Callus formation and the rate of healing of femoral fractures in patients with head injuries J. Bone Jt. Surg. Br. 1987 69 521 524 10.1302/0301-620X.69B4.3611150 46. Locher RJ Traumatic brain injury and bone healing: radiographic and biomechanical analyses of bone formation and stability in a combined murine trauma model J. Musculoskelet. Neuronal Interact. 2015 15 309 315 26636276 47. Tsitsilonis S The effect of traumatic brain injury on bone healing: an experimental study in a novel in vivo animal model Injury 2015 46 661 665 10.1016/j.injury.2015.01.044 25682315 48. Wang L Effect of leptin on bone metabolism in rat model of traumatic brain injury and femoral fracture Chin. J. Traumatol. 2011 14 7 13 21276361 49. Wei Y Wang L Clark JC Dass CR Choong PF Elevated leptin expression in a rat model of fracture and traumatic brain injury J. Pharm. Pharmacol. 2008 60 1667 1672 10.1211/jpp.60.12.0013 19000372 50. Liu X SDF-1 promotes endochondral bone repair during fracture healing at the traumatic brain injury condition PloS ONE 2013 8 e54077 10.1371/journal.pone.0054077 23349789 51. Brady RD Closed head experimental traumatic brain injury increases size and bone volume of callus in mice with concomitant tibial fracture Sci. Rep. 2016 6 34491 10.1038/srep34491 27682431 52. Wang L The effects of spinal cord injury on bone healing in patients with femoral fractures J. Spinal Cord Med. 2014 37 414 419 10.1179/2045772313Y.0000000155 24621032 53. Morioka K Differential fracture response to traumatic brain injury suggests dominance of neuroinflammatory response in polytrauma Sci. Rep. 2019 9 1 16 10.1038/s41598-018-37186-2 30626917 54. Brady RD Experimental traumatic brain injury induces bone loss in rats J. Neurotrauma 2016 33 2154 2160 10.1089/neu.2014.3836 25686841 55. Brady R Sodium selenate treatment mitigates reduction of bone volume following traumatic brain injury in rats J. Musculoskelet. Neuronal Interact. 2016 16 369 376 27973389 56. Kaplan FS Glaser DL Hebela N Shore EM Heterotopic ossification J. Am. Acad. Orthop. Surg. 2004 12 116 125 10.5435/00124635-200403000-00007 15089085 57. Shimono K Uchibe K Kuboki T Iwamoto M The pathophysiology of heterotopic ossification: current treatment considerations in dentistry Jpn. Dent. Sci. Rev. 2014 50 1 8 10.1016/j.jdsr.2013.07.003 58. Edwards DS Clasper J Heterotopic ossification: a systematic review J. R. Army Med. Corps 2015 161 315 321 10.1136/jramc-2014-000277 25015927 59. Shore EM Kaplan FS Inherited human diseases of heterotopic bone formation Nat. Rev. Rheumatol. 2010 6 518 527 10.1038/nrrheum.2010.122 20703219 60. Kan C Conserved signaling pathways underlying heterotopic ossification Bone 2018 109 43 48 10.1016/j.bone.2017.04.014 28455214 61. Hwang C Mesenchymal VEGFA induces aberrant differentiation in heterotopic ossification Bone Res. 2019 7 1 17 10.1038/s41413-019-0075-6 30622830 62. Robins JC Hypoxia induces chondrocyte-specific gene expression in mesenchymal cells in association with transcriptional activation of Sox9 Bone 2005 37 313 322 10.1016/j.bone.2005.04.040 16023419 63. Stegen S van Gastel N Carmeliet G Bringing new life to damaged bone: the importance of angiogenesis in bone repair and regeneration Bone 2015 70 19 27 10.1016/j.bone.2014.09.017 25263520 64. Qureshi AT Early characterization of blast-related heterotopic ossification in a rat model Clin. Orthop. Relat. Res. 2015 473 2831 2839 10.1007/s11999-015-4240-y 25754758 65. Agarwal S Diminished chondrogenesis and enhanced osteoclastogenesis in leptin-deficient diabetic mice (ob/ob) impair pathologic, trauma-induced heterotopic ossification Stem Cells Dev. 2015 24 2864 2872 10.1089/scd.2015.0135 26413838 66. Allen, M. R. & Burr, D. B. in Basic and Applied Bone Biology (eds David, B. Burr & Matthew, R. Allen) 75–90 (Academic Press, 2014). 67. Chalmers J Gray D Rush J Observations on the induction of bone in soft tissues J. Bone Jt. Surg. Br. 1975 57 36 45 10.1302/0301-620X.57B1.36 68. Davies OG Grover LM Eisenstein N Lewis MP Liu Y Identifying the cellular mechanisms leading to heterotopic ossification Calcif. Tissue Int. 2015 97 432 444 10.1007/s00223-015-0034-1 26163233 69. Lees-Shepard JB Goldhamer DJ Stem cells and heterotopic ossification: lessons from animal models Bone 2018 109 178 186 10.1016/j.bone.2018.01.029 29409971 70. Foley KL Hebela N Keenan MA Pignolo RJ Histopathology of periarticular non-hereditary heterotopic ossification Bone 2018 109 65 70 10.1016/j.bone.2017.12.006 29225159 71. Dey D The traumatic bone: trauma-induced heterotopic ossification Transl. Res. 2017 186 95 111 10.1016/j.trsl.2017.06.004 28668522 72. Meyers C Heterotopic ossification: a comprehensive review JBMR Plus 2019 3 e10172 10.1002/jbm4.10172 31044187 73. Łęgosz P Drela K Pulik Ł Sarzyńska S Małdyk P Challenges of heterotopic ossification—molecular background and current treatment strategies Clin. Exp. Pharmacol. Physiol. 2018 45 1229 1235 10.1111/1440-1681.13025 30144316 74. Ranganathan K Heterotopic ossification: basic-science principles and clinical correlates J. Bone Jt. Surg. Br. 2015 97 1101 1111 10.2106/JBJS.N.01056 75. Xu R Hu J Zhou X Yang Y Heterotopic ossification: mechanistic insights and clinical challenges Bone 2018 109 134 142 10.1016/j.bone.2017.08.025 28855144 76. Sorkin M Regulation of heterotopic ossification by monocytes in a mouse model of aberrant wound healing Nat. Commun. 2020 11 1 17 10.1038/s41467-019-14172-4 31911652 77. Tseng, H. W. et al. Neurogenic heterotopic ossifications develop independently of granulocyte‐colony stimulating factor and neutrophils. J. Bone Miner. Res. 1–10 (2020). 78. Torossian, F. et al. Macrophage-derived oncostatin M contributes to human and mouse neurogenic heterotopic ossifications. JCI Insight2, e96034 (2017). 79. Suda RK Circulating osteogenic precursor cells in heterotopic bone formation Stem Cells 2009 27 2209 2219 10.1002/stem.150 19522009 80. Sims, N. A. & Quinn, J. M. Osteoimmunology: oncostatin M as a pleiotropic regulator of bone formation and resorption in health and disease. Bonekey Rep.3, 527 (2014). 81. Brady RD A novel rat model of heterotopic ossification after polytrauma with traumatic brain injury Bone 2020 133 115263 10.1016/j.bone.2020.115263 32032779 82. Hausmann OB Post-traumatic inflammation following spinal cord injury Spinal Cord 2003 41 369 378 10.1038/sj.sc.3101483 12815368 83. Chodobski A Zink BJ Szmydynger-Chodobska J Blood–brain barrier pathophysiology in traumatic brain injury Transl. Stroke Res. 2011 2 492 516 10.1007/s12975-011-0125-x 22299022 84. Werner C Engelhard K Pathophysiology of traumatic brain injury BJA Br. J. Anaesth. 2007 99 4 9 10.1093/bja/aem131 17573392 85. Nimmo A Neurogenic inflammation is associated with development of edema and functional deficits following traumatic brain injury in rats Neuropeptides 2004 38 40 47 10.1016/j.npep.2003.12.003 15003715 86. Bajwa NM Kesavan C Mohan S Long-term consequences of traumatic brain injury in bone metabolism Front. Neurol. 2018 9 115 10.3389/fneur.2018.00115 29556212 87. Payan DG Neuropeptides and inflammation: the role of substance P Annu. Rev. Med. 1989 40 341 352 10.1146/annurev.me.40.020189.002013 2471450 88. Azuma H Kido Ji, Ikedo D Kataoka M Nagata T Substance P enhances the inhibition of osteoblastic cell differentiation induced by lipopolysaccharide from porphyromonas gingivalis J. Periodontol. 2004 75 974 981 10.1902/jop.2004.75.7.974 15341355 89. Kan L Substance P signaling mediates BMP‐dependent heterotopic ossification J. Cell. Biochem. 2011 112 2759 2772 10.1002/jcb.23259 21748788 90. Salisbury E Sensory nerve induced inflammation contributes to heterotopic ossification J. Cell. Biochem. 2011 112 2748 2758 10.1002/jcb.23225 21678472 91. Goto T Substance P stimulates late-stage rat osteoblastic bone formation through neurokinin-1 receptors Neuropeptides 2007 41 25 31 10.1016/j.npep.2006.11.002 17204323 92. Sharma HS Nyberg F Olsson Y Dey PK Alteration of substance P after trauma to the spinal cord: an experimental study in the rat Neuroscience 1990 38 205 212 10.1016/0306-4522(90)90386-I 1701525 93. Donkin JJ Turner RJ Hassan I Vink R Substance P in traumatic brain injury Prog. Brain Res. 2007 161 97 109 10.1016/S0079-6123(06)61007-8 17618972 94. Medici D Olsen BR The role of endothelial‐mesenchymal transition in heterotopic ossification J. Bone Miner. Res. 2012 27 1619 1622 10.1002/jbmr.1691 22806925 95. Reichel LM Salisbury E Moustoukas MJ Davis AR Olmsted-Davis E Molecular mechanisms of heterotopic ossification J. Hand Surg. 2014 39 563 566 10.1016/j.jhsa.2013.09.029 96. Salisbury, E., Sonnet, C., Heggeness, M., Davis, A. R. & Olmsted-Davis, E. Heterotopic ossification has some nerve. Crit. Rev. Eukaryot. Gene Expr. 20, 313–324 (2010). 97. Pearn ML Pathophysiology associated with traumatic brain injury: current treatments and potential novel therapeutics Cell. Mol. Neurobiol. 2017 37 571 585 10.1007/s10571-016-0400-1 27383839 98. Vink R van den Heuvel C Substance P antagonists as a therapeutic approach to improving outcome following traumatic brain injury Neurotherapeutics 2010 7 74 80 10.1016/j.nurt.2009.10.018 20129499 99. González-Hernández, A. et al. Heteroreceptors modulating CGRP release at neurovascular junction: potential therapeutic implications on some vascular-related diseases. Biomed Res. Int.2016, 2056786 (2016). 100. Irie K Hara‐Irie F Ozawa H Yajima T Calcitonin gene‐related peptide (CGRP)‐containing nerve fibers in bone tissue and their involvement in bone remodeling Microsc. Res. Tech. 2002 58 85 90 10.1002/jemt.10122 12203707 101. Sang X Wang Z Shi P Li Y Cheng L CGRP accelerates the pathogenesis of neurological heterotopic ossification following spinal cord injury Artif. Cells Nanomed. Biotechnol. 2019 47 2569 2574 10.1080/21691401.2019.1626865 31219353 102. Song Y Increased levels of calcitonin gene-related peptide in serum accelerate fracture healing following traumatic brain injury Mol. Med. Rep. 2012 5 432 438 22038198 103. Song Y The role of the hippocampus and the function of calcitonin gene-related peptide in the mechanism of traumatic brain injury accelerating fracture-healing Eur. Rev. Med. Pharmacol. Sci. 2017 21 1522 1531 28429354 104. Zhang D The influence of brain injury or peripheral nerve injury on calcitonin gene-related peptide concentration variation and fractures healing process Artif. Cells Blood Substit. Biotechnol. 2009 37 85 91 10.1080/10731190902743149 105. Sofroniew MV Howe CL Mobley WC Nerve growth factor signaling, neuroprotection, and neural repair Annu. Rev. Neurosci. 2001 24 1217 1281 10.1146/annurev.neuro.24.1.1217 11520933 106. Tomlinson RyanE NGF-TrkA signaling by sensory nerves coordinates the vascularization and ossification of developing endochondral bone Cell Rep. 2016 16 2723 2735 10.1016/j.celrep.2016.08.002 27568565 107. Grills BL Schuijers JA Immunohistochemical localization of nerve growth factor in fractured and unfractured rat bone Acta Orthop. Scand. 1998 69 415 419 10.3109/17453679808999059 9798454 108. Li X Sun D Li Y Wu X Neurotrophin-3 improves fracture healing in rats Eur. Rev. Med. Pharmacol. Sci. 2018 22 2439 2446 29762846 109. Asaumi K Nakanishi T Asahara H Inoue H Takigawa M Expression of neurotrophins and their receptors (TRK) during fracture healing Bone 2000 26 625 633 10.1016/S8756-3282(00)00281-7 10831935 110. Zhang, J. et al. Macrophage-derived neurotrophin-3 promotes heterotopic ossification in rats. Lab. Investig.100, 762–776 (2020). 111. Corr A Smith J Baldock P Neuronal control of bone remodeling Toxicol. Pathol. 2017 45 894 903 10.1177/0192623317738708 29113558 112. Otto E Crosstalk of brain and bone—clinical observations and their molecular bases Int. J. Mol. Sci. 2020 21 4946 10.3390/ijms21144946 7404044 113. Takeda S Leptin regulates bone formation via the sympathetic nervous system Cell 2002 111 305 317 10.1016/S0092-8674(02)01049-8 12419242 114. Chao ST Joyce MJ Suh JH Treatment of heterotopic ossification Orthopedics 2007 30 457 464 10.3928/01477447-20070601-18 17598490 115. Shehab D Elgazzar AH Collier BD Heterotopic ossification J. Nucl. Med. 2002 43 346 353 11884494 116. Ebinger T Roesch M Kiefer H Kinzl L Schulte M Influence of etiology in heterotopic bone formation of the hip J. Trauma Acute Care Surg. 2000 48 1058 1062 10.1097/00005373-200006000-00010 117. Subbarao JV Garrison SJ Heterotopic ossification: diagnosis and management current concepts and controversies J. Spinal Cord. Med. 1999 22 273 283 10.1080/10790268.1999.11719580 10751131 118. Sullivan M Torres S Mehta S Ahn J Heterotopic ossification after central nervous system trauma: a current review Bone Jt. Res. 2013 2 51 57 10.1302/2046-3758.23.2000152 119. Almangour W Recurrence of heterotopic ossification after removal in patients with traumatic brain injury: a systematic review Ann. Phys. Rehabil. Med. 2016 59 263 269 10.1016/j.rehab.2016.03.009 27173174 120. Genet F Impact of the operative delay and the degree of neurologic sequelae on recurrence of excised heterotopic ossification in patients with traumatic brain injury J. Head Trauma Rehabil. 2012 27 443 448 10.1097/HTR.0b013e31822b54ba 22495100 121. Genet F Beliefs relating to recurrence of heterotopic ossification following excision in patients with spinal cord injury: a review Spinal Cord 2015 53 340 344 10.1038/sc.2015.20 25687517 122. Genêt F Impact of late surgical intervention on heterotopic ossification of the hip after traumatic neurological injury J. Bone Jt. Surg. Br. 2009 91 1493 1498 10.1302/0301-620X.91B11.22305 123. Agarwal S Surgical excision of heterotopic ossification leads to re-emergence of mesenchymal stem cell populations responsible for recurrence Stem Cells Transl. Med. 2017 6 799 806 10.5966/sctm.2015-0365 28297577 124. Melamed E Brain injury-related heterotopic bone formation: treatment strategy and results Am. J. Phys. Med. Rehabil. 2002 81 670 674 10.1097/00002060-200209000-00006 12172519 125. van Kuijk AA Geurts ACH van Kuppevelt HJM Neurogenic heterotopic ossification in spinal cord injury Spinal Cord 2002 40 313 326 10.1038/sj.sc.3101309 12080459 126. Pavey GJ What risk factors predict recurrence of heterotopic ossification after excision in combat-related amputations? Clin. Orthop. Relat. Res. 2015 473 2814 2824 10.1007/s11999-015-4266-1 25832006 127. Barfield WR Holmes RE Hartsock LA Heterotopic ossification in trauma Orthop. Clin. 2017 48 35 46 10.1016/j.ocl.2016.08.009 128. Potter BK Burns TC Lacap AP Granville RR Gajewski DA Heterotopic ossification following traumatic and combat-related amputations: prevalence, risk factors, and preliminary results of excision J. Bone Jt. Surg. Am. 2007 89 476 486 10.2106/00004623-200703000-00003 129. Tsionos I Leclercq C Rochet JM Heterotopic ossification of the elbow in patients with burns J. Bone Jt. Surg. Br. 2004 86-B 396 403 10.1302/0301-620X.86B3.14480 130. Pohl F Radiation-induced suppression of the Bmp2 signal transduction pathway in the pluripotent mesenchymal cell line C2C12: an in vitro model for prevention of heterotopic ossification by radiotherapy Radiat. Res. 2003 159 345 350 10.1667/0033-7587(2003)159[0345:RISOTB]2.0.CO;2 12600237 131. Szymczyk K Shapiro I Adams CS Ionizing radiation sensitizes bone cells to apoptosis Bone 2004 34 148 156 10.1016/j.bone.2003.09.003 14751572 132. Craven PL URIsT MR Osteogenesis by radioisotope labelled cell populations in implants of bone matrix under the influence of ionizing radiation Clin. Orthop. Relat. Res. 1971 76 231 243 10.1097/00003086-197105000-00030 4931060 133. Sautter-Bihl M Liebermeister E Nanassy A Radiotherapy as a local treatment option for heterotopic ossifications in patients with spinal cord injury Spinal Cord 2000 38 33 36 10.1038/sj.sc.3100847 10762195 134. Hamid N Radiation therapy for heterotopic ossification prophylaxis acutely after elbow trauma: a prospective randomized study J. Bone Jt. Surg. Am. 2010 92 2032 2038 10.2106/JBJS.I.01435 135. Burd TA Lowry KJ Anglen JO Indomethacin compared with localized irradiation for the prevention of heterotopic ossification following surgical treatment of acetabular fractures J. Bone Jt. Surg. Am. 2001 83 1783 1788 10.2106/00004623-200112000-00003 136. Haubner F Ohmann E Pohl F Strutz J Gassner HG Wound healing after radiation therapy: review of the literature Radiat. Oncol. 2012 7 162 10.1186/1748-717X-7-162 23006548 137. Farris MK Chowdhry VK Lemke S Kilpatrick M Lacombe M Osteosarcoma following single fraction radiation prophylaxis for heterotopic ossification Radiat. Oncol. 2012 7 1 6 10.1186/1748-717X-7-140 22214341 138. Banovac K Williams JM Patrick LD Haniff YM Prevention of heterotopic ossification after spinal cord injury with indomethacin Spinal Cord 2001 39 370 374 10.1038/sj.sc.3101166 11464310 139. DiCesare PE Nimni ME Peng L Yazdi M Cheung DT Effects of indomethacin on demineralized bone‐induced heterotopic ossification in the rat J. Orthop. Res. 1991 9 855 861 10.1002/jor.1100090611 1919848 140. Sibbald B Drug Regulation: Rofecoxib (Vioxx) voluntarily withdrawn from market Can. Med. Assoc. J. 2004 171 1027 1028 10.1503/cmaj.1041606 15505253 141. Rø J Sudmann E Marton PF Effect of indomethacin on fracture healing in rats Acta Orthop. Scand. 1976 47 588 599 10.3109/17453677608988744 1015253 142. Baird EO Kang QK Prophylaxis of heterotopic ossification–an updated review J. Orthop. Surg. Res. 2009 4 12 10.1186/1749-799X-4-12 19379483 143. Browne KD Iwata A Putt ME Smith DH Chronic ibuprofen administration worsens cognitive outcome following traumatic brain injury in rats Exp. Neurol. 2006 201 301 307 10.1016/j.expneurol.2006.04.008 16764859 144. Dash PK Mach SA Moore A N. Regional expression and role of cyclooxygenase-2 following experimental traumatic brain injury J. Neurotrauma 2000 17 69 81 10.1089/neu.2000.17.69 10674759 145. Suleyman H Demircan B Karagoz Y Anti-inflammatory and side effects of cyclo-oxygenase inhibitors Pharmacol. Rep. 2007 59 247 258 17652824 146. Green GA Understanding NSAIDs: from aspirin to COX-2 Clin. Cornerstone 2001 3 50 59 10.1016/S1098-3597(01)90069-9 11464731 147. Drake, M. T., Clarke, B. L. & Khosla, S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin. Proc. 83, 1032–1045 (2008). 148. Russell RGG Bisphosphonates: mode of action and pharmacology Pediatrics 2007 119 S150 S162 10.1542/peds.2006-2023H 17332236 149. Manzano-Moreno FJ Ramos-Torrecillas J De Luna-Bertos E Ruiz C García-Martínez O High doses of bisphosphonates reduce osteoblast-like cell proliferation by arresting the cell cycle and inducing apoptosis J. Cranio-Maxillofac. Surg. 2015 43 396 401 10.1016/j.jcms.2014.12.008 150. Idris AI Rojas J Greig IR van’t Hof RJ Ralston SH Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro Calcif. Tissue Int. 2008 82 191 201 10.1007/s00223-008-9104-y 18259679 151. Garland, D. E., Alday, B., Venos, K. G. & Vogt, J. C. Diphosphonate treatment for heterotopic ossification in spinal cord injury patients. Clin. Orthop. Relat. Res.176, 197–200 (1983). 152. Banovac K Gonzalez F Wade N Bowker JJ Intravenous disodium etidronate therapy in spinal cord injury patients with heterotopic ossification Spinal Cord 1993 31 660 666 10.1038/sc.1993.106 153. Banovac K Gonzalez F Renfree KJ Treatment of heterotopic ossification after spinal cord injury J. Spinal Cord Med. 1997 20 60 65 10.1080/10790268.1997.11719457 9097258 154. Banovac K The effect of etidronate on late development of heterotopic ossification after spinal cord injury J. Spinal Cord Med. 2000 23 40 44 10.1080/10790268.2000.11753507 10752873 155. Mashiba T Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib J. Bone Miner. Res. 2000 15 613 620 10.1359/jbmr.2000.15.4.613 10780852 156. Burr DB Bone microdamage and skeletal fragility in osteoporotic and stress fractures J. Bone Miner. Res. 1997 12 6 15 10.1359/jbmr.1997.12.1.6 9240720 157. Vasileiadis G Prevention of heterotopic ossification in cases of hypertrophic osteoarthritis submitted to total hip arthroplasty. Etidronate or Indomethacin J. Musculoskelet. Neuronal Interact. 2010 10 159 165 20516633 158. Williams JA Retinoic acid receptors are required for skeletal growth, matrix homeostasis and growth plate function in postnatal mouse Dev. Biol. 2009 328 315 327 10.1016/j.ydbio.2009.01.031 19389355 159. Pavey GJ Targeted stimulation of retinoic acid receptor-γ mitigates the formation of heterotopic ossification in an established blast-related traumatic injury model Bone 2016 90 159 167 10.1016/j.bone.2016.06.014 27368930 160. Shimono K Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-γ agonists Nat. Med. 2011 17 454 460 10.1038/nm.2334 21460849 161. Yasuhara R Wnt/β-catenin and retinoic acid receptor signaling pathways interact to regulate chondrocyte function and matrix turnover J. Biol. Chem. 2010 285 317 327 10.1074/jbc.M109.053926 19858186 162. De Luca, F. et al. Retinoic acid is a potent regulator of growth plate chondrogenesis. Endocrinology141, 346–353 (2000). 163. Shimono K Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-gamma agonists Nat. Med. 2011 17 454 460 10.1038/nm.2334 21460849 164. Pavey GJ Targeted stimulation of retinoic acid receptor-gamma mitigates the formation of heterotopic ossification in an established blast-related traumatic injury model Bone 2016 90 159 167 10.1016/j.bone.2016.06.014 27368930 165. Reznik J Prevalence and risk-factors of neurogenic heterotopic ossification in traumatic spinal cord and traumatic brain injured patients admitted to specialised units in Australia J. Musculoskelet. Neuronal Interact. 2014 14 19 28 24583537 166. Rigaux P Study of serum factors potentially involved in the pathogenesis of heterotopic bone formation after severe brain injury Jt. Bone Spine 2005 72 146 149 10.1016/j.jbspin.2004.05.012 167. Hurvitz EA Mandac BR Davidoff G Johnson JH Nelson VS Risk factors for heterotopic ossification in children and adolescents with severe traumatic brain injury Arch. Phys. Med. Rehabil. 1992 73 459 462 1580774 168. Hendricks HT Geurts A van Ginneken BC Heeren AJ Vos PE Brain injury severity and autonomic dysregulation accurately predict heterotopic ossification in patients with traumatic brain injury Clin. Rehabil. 2007 21 545 553 10.1177/0269215507075260 17613585 169. Seipel R Neurogenic heterotopic ossification: epidemiology and morphology on conventional radiographs in an early neurological rehabilitation population Skelet. Radiol. 2012 41 61 66 10.1007/s00256-011-1115-5 170. Singh RS Craig MC Katholi CR Jackson AB Mountz JM The predictive value of creatine phosphokinase and alkaline phosphatase in identification of heterotopic ossification in patients after spinal cord injury Arch. Phys. Med. Rehabil. 2003 84 1584 1588 10.1053/S0003-9993(03)00347-2 14639555 171. Wittenberg R Peschke U Botel U Heterotopic ossification after spinal cord injury. Epidemiology and risk factors J. Bone Jt. Surg. Br. 1992 74 215 218 10.1302/0301-620X.74B2.1544955 172. Bravo-Payno P Esclarin A Arzoz T Arroyo O Labarta C Incidence and risk factors in the appearance of heterotopic ossification in spinal cord injury Spinal Cord 1992 30 740 745 10.1038/sc.1992.142 173. Orzel JA Rudd TG Heterotopic bone formation: clinical, laboratory, and imaging correlation J. Nucl. Med. 1985 26 125 132 3918147 174. Meiners T Abel R Böhm V Gerner H Resection of heterotopic ossification of the hip in spinal cord injured patients Spinal Cord 1997 35 443 445 10.1038/sj.sc.3100415 9232749 175. Hunt JL Arnoldo BD Kowalske K Helm P Purdue GF Heterotopic ossification revisited: a 21-year surgical experience J. Burn Care Res. 2006 27 535 540 10.1097/01.BCR.0000226023.58438.14 16819361 176. Stein DA Prevention of heterotopic ossification at the elbow following trauma using radiation therapy Bull. Hosp. Jt. Dis. N.Y. 2003 61 151 154 177. Müseler A In-hospital outcomes following single-dose radiation therapy in the treatment of heterotopic ossification of the hip following spinal cord injury—an analysis of 444 cases Spinal Cord 2017 55 244 246 10.1038/sc.2016.112 27431658 178. Cipriano, C., Pill, S. G., Rosenstock, J. & Keenan, M. A. Radiation therapy for preventing recurrence of neurogenic heterotopic ossification. Orthopedics32, 685–689 (2009). 179. Banovac K Williams J Patrick L Levi A Prevention of heterotopic ossification after spinal cord injury with COX-2 selective inhibitor (rofecoxib) Spinal Cord 2004 42 707 710 10.1038/sj.sc.3101628 15179440 180. Romanò CL Duci D Romanò D Mazza M Meani E Celecoxib versus indomethacin in the prevention of heterotopic ossification after total hip arthroplasty J. Arthroplast. 2004 19 14 18 10.1016/S0883-5403(03)00279-1 181. Schmidt SA The use of indomethacin to prevent the formation of heterotopic bone after total hip replacement. A randomized, double-blind clinical trial J. Bone Jt. Surg. Am. 1988 70 834 838 10.2106/00004623-198870060-00005 182. Bedi A The incidence of heterotopic ossification after hip arthroscopy Am. J. Sports Med. 2012 40 854 863 10.1177/0363546511434285 22268230 183. Beckmann JT Effect of naproxen prophylaxis on heterotopic ossification following hip arthroscopy: a double-blind randomized placebo-controlled trial J. Bone Jt. Surg. Am. 2015 97 2032 2037 10.2106/JBJS.N.01156 184. Neal BC No effect of low-dose aspirin for the prevention of heterotopic bone formation after total hip replacement: a randomized trial of 2 649 patients Acta Orthop. Scand. 2000 71 129 134 10.1080/000164700317413085 10852317 185. Schuetz P Mueller B Christ-Crain M Dick W Haas H Amino-bisphosphonates in heterotopic ossification: first experience in five consecutive cases Spinal Cord 2005 43 604 610 10.1038/sj.sc.3101761 15867938